oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Department of Obstetrics and Gynecology.
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Örebro University Hospital. Department of Obstetrics and Gynecology.
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2013 (English)In: Menopause: The Journal of the North American Menopause, ISSN 1072-3714, E-ISSN 1530-0374, Vol. 20, no 2, 162-168 p.Article in journal (Refereed) Published
Abstract [en]

Objective: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.

Methods: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.

Results: In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitorYtreated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.

Conclusions: Our findings suggest that sexual dysfunction in aromatase inhibitorYtreated women is a greatly underestimated problem.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2013. Vol. 20, no 2, 162-168 p.
Keyword [en]
Aromatase inhibitors, Breast cancer, Postmenopausal women, Sexual dysfunction, Tamoxifen
National Category
Family Medicine
Identifiers
URN: urn:nbn:se:oru:diva-54872DOI: 10.1097/gme.0b013e31826560daISI: 000314342600010PubMedID: 22990756Scopus ID: 2-s2.0-84873409411OAI: oai:DiVA.org:oru-54872DiVA: diva2:1066943
Funder
Swedish Cancer Society, CAN 2009/773Swedish Research Council, VR 621-2008-3562
Note

Funding Agency:

Uppsala-Örebro Regional Research Council 

Lions Clubs International 

Percy Falk Foundation 

Available from: 2017-01-19 Created: 2017-01-19 Last updated: 2017-10-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Baumgart, JulianeNilsson, Kerstin
By organisation
School of Health and Medical Sciences, Örebro University, SwedenÖrebro University Hospital
In the same journal
Menopause: The Journal of the North American Menopause
Family Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 34 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf